检索结果 - Chul‐min Lee

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

    A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors 由 Juneko E. Grilley‐Olson, Philippe L. Bédard, Angelica Fasolo, Mark Cornfeld, Leanne Cartee, A.R. Abdul Razak, Lee-Anne Stayner, Yuhui Wu, Ryan Greenwood, R. Singh, Chul‐min Lee, Johanna C. Bendell, Howard A. Burris, Gianluca Del Conte, Cristiana Sessa, Jeffrey R. Infante

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

    Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors 由 Matthew D. Hellmann, T. W. Kim, Chul‐min Lee, B-C. Goh, Wilson H. Miller, Do‐Youn Oh, R. Jamal, C.E. Chee, Laura Q.M. Chow, Justin F. Gainor, Jayesh Desai, Benjamin Solomon, Meghna Das Thakur, Bethany Pitcher, Paul Foster, Genevive Hernandez, Matthew Wongchenko, Edward Cha, Yu Jeong Bang, Lillian L. Siu, Johanna C. Bendell

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: